Related references
Note: Only part of the references are listed.Pharmacogenetic and clinical predictors of ondansetron failure in a diverse pediatric oncology population
Shana S. Jacobs et al.
SUPPORTIVE CARE IN CANCER (2022)
Genetic contribution to PONV risk
Stefanie Klenke et al.
ANAESTHESIA CRITICAL CARE & PAIN MEDICINE (2020)
Fourth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting
Tong J. Gan et al.
ANESTHESIA AND ANALGESIA (2020)
Pharmacogenetics of antiemetics for chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis
Astrid Eliasen et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2020)
Genetic variability in postoperative nausea and vomiting A systematic review
Stefanie Klenke et al.
EUROPEAN JOURNAL OF ANAESTHESIOLOGY (2020)
Is there a place for genetics in the management of PONV?
Keith Candiotti et al.
BEST PRACTICE & RESEARCH-CLINICAL ANAESTHESIOLOGY (2020)
Pharmacogenetics of Postoperative Nausea and Vomiting
Edwin N. Aroke et al.
JOURNAL OF PERIANESTHESIA NURSING (2019)
Genetic Factors Associated with Postoperative Nausea and Vomiting: a Systematic Review
Pedro Lopez-Morales et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2018)
CYP2D6 basic genotyping as a potential tool to improve the antiemetic efficacy of ondansetron in prophylaxis of postoperative nausea and vomiting
Przemyslaw A. Niewinski et al.
ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE (2018)
Effect of the allelic variants of ABCB1, CYP2D6 and HTR3B on response of ramosetron to prevent chemotherapy-induced nausea and vomiting in Korean cancer patients
Gaeun Kang et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2017)
Influence of ABCB1 and ABCG2 polymorphisms on the antiemetic efficacy in patients with cancer receiving cisplatin-based chemotherapy: a TRIPLE pharmacogenomics study
D. Tsuji et al.
PHARMACOGENOMICS JOURNAL (2017)
Comparison of Ramosetron and Palonosetron for Preventing Nausea and Vomiting after Spinal Surgery: Association With ABCB1 Polymorphisms
Jong Wook Song et al.
JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY (2017)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron
G. C. Bell et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Development and use of molecular markers: past and present
Atul Grover et al.
CRITICAL REVIEWS IN BIOTECHNOLOGY (2016)
Association of 5-HT3B Receptor Gene Polymorphisms with the Efficacy of Ondansetron for Postoperative Nausea and Vomiting
Min-Soo Kim et al.
YONSEI MEDICAL JOURNAL (2015)
Genetic factors associated with pharmacotherapy and background sensitivity to postoperative and chemotherapy-induced nausea and vomiting
Piotr K. Janicki et al.
EXPERIMENTAL BRAIN RESEARCH (2014)
The Association of CYP2D6 Genotype and Postoperative Nausea and Vomiting in Orthopedic Trauma Patients
Susan W. Wesmiller et al.
BIOLOGICAL RESEARCH FOR NURSING (2013)
P-glycoprotein ABCB1: a major player in drug handling by mammals
Piet Borst et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Pharmacogenetics in perioperative medicine
Mindy Cohen et al.
CURRENT OPINION IN ANESTHESIOLOGY (2012)
5-HT3 receptors: potential of individual isoforms for personalised therapy
Beate Niesler
CURRENT OPINION IN PHARMACOLOGY (2011)
Association of ABCB1, 5-HT3B Receptor and CYP2D6 Genetic Polymorphisms with Ondansetron and Metoclopramide Antiemetic Response in Indonesian Cancer Patients Treated with Highly Emetogenic Chemotherapy
Dyah A. Perwitasari et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2011)
Association of ABCB1 polymorphisms with the efficacy of ondansetron for postoperative nausea and vomiting
E. M. Choi et al.
ANAESTHESIA (2010)
Polymorphism in HTR3D shows different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy
Christian Hammer et al.
PHARMACOGENOMICS (2010)
Do Variations in the 5-HT3A and 5-HT3B Serotonin Receptor Genes (HTR3A and HTR3B) Influence the Occurrence of Postoperative Vomiting?
Henrik Rueffert et al.
ANESTHESIA AND ANALGESIA (2009)
Genetic polymorphisms in the cytochrome P450 system and efficacy of 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting
M. Nielsen et al.
BRITISH JOURNAL OF ANAESTHESIA (2008)
Polymorphisms in the novel serotonin receptor subunit gene HTR3C show different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy
P. A. Fasching et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2008)
Serotonin type 3 receptor genes:: HTR3A, B, C, D, E
Beate Niesler et al.
PHARMACOGENOMICS (2008)
Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes
Werner Schroth et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Pharmacology, pharmacogenetics, and clinical efficacy of 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting
Kok-Yuen Ho et al.
CURRENT OPINION IN ANESTHESIOLOGY (2006)
The effect of 5-hydroxytryptamine 3A and 3B receptor genes on nausea induced by paroxetine
T. Sugai et al.
PHARMACOGENOMICS JOURNAL (2006)
Prevention of postoperative nausea and vomiting with granisetron and dolasetron in relation to CYP2D6 genotype
PK Janicki et al.
ANESTHESIA AND ANALGESIA (2006)
Interethnic differences in genetic polymorphisms of CYP2D6 in the US population: Clinical implications
Stephen Bernard et al.
ONCOLOGIST (2006)
Genetic testing for pharmacogenetics and its clinical application in drug therapy
M Hiratsuka et al.
CLINICA CHIMICA ACTA (2006)
Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists
MO Babaoglu et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
The impact of pharmacogenomics on postoperative nausea and vomiting - Do CYP2D6 allele copy number and polymorphisms affect the success or failure of ondansetron prophylaxis?
KA Candiotti et al.
ANESTHESIOLOGY (2005)
Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting - Are they all the same?
TJ Gan
CNS DRUGS (2005)
Investigation of the association between 5-HT3A receptor gene polymorphisms and efficiency of antiemetic treatment with 5-HT3 receptor antagonists
R Kaiser et al.
PHARMACOGENETICS (2004)
Polymorphisms in human MDR1 (P-glycoprotein): Recent advances and clinical relevance
C Marzolini et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients
PB Tremblay et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Effect of the CYP2D6 genotype on the pharmacokinetics of tropisetron in healthy Korean subjects
MK Kim et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2003)
5-HT3-receptor antagonists and the cytochrome P450 system:: Clinical implications
PR Blower
CANCER JOURNAL (2002)
Contribution of P-glycoprotein to efflux of ramosetron, a 5-HT3 receptor antagonist, across the blood-brain barrier
C Yamamoto et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2002)
Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes
R Kaiser et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Share Paper
